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RESUMO 
 
A artrite reumatoide (AR) é uma doença autoimune crónica, sistémica e de etiologia 
desconhecida, que afeta cerca de 0,5-1% da população mundial. A AR é caracterizada por 
uma poliartrite simétrica associada a dor e tumefação de múltiplas articulações, em 
particular das pequenas articulações das mãos. Embora não exista ainda cura para a AR, 
sabe-se que um tratamento adequado, assim como um diagnóstico precoce são de extrema 
importância para o doente e para a sociedade em geral. Se não for corretamente tratada, a 
AR conduz a destruição óssea e articular. Deste modo, é crucial que a terapêutica seja a 
mais adequada possível ao estado clínico do doente e implementada na fase inicial do curso 
da doença. 
 
O tratamento da AR tem como principais objetivos a preservação da função e qualidade de 
vida do doente, minimizando a dor e sinais inflamatórios, a remissão e controlo das 
manifestações sistémicas. Os primeiros tratamentos administrados aos doentes com AR são 
drogas anti-inflamatórias não esteróides e corticóides, úteis no alívio dos sintomas clínicos e 
na diminuição da inflamação. Contudo, torna-se primordial o uso de drogas antirreumáticas 
modificadoras da doença como, por exemplo, o metotrexato (MTX), eficaz no controlo da 
atividade e progressão da doença. Todavia, a introdução das terapias biológicas como as 
drogas anti-fator de necrose tumoral (anti-TNF) ou o anticorpo monoclonal bloqueador do 
recetor da interleucina-6 (IL-6R) tocilizumab (TCZ), possibilitou atingir uma melhoria 
considerável na inibição da progressão da doença.  
Várias doenças autoimunes são dependentes de células B, principalmente através da 
produção de autoanticorpos, tal como a AR. Estudos anteriores revelaram a importância das 
células B na patogénese da AR através de diversos mecanismos. As células B produzem 
autoanticorpos, como o fator reumatoide (FR) e anticorpos anti-proteínas citrulinadas 
(ACPA), que formam complexos imunes que se depositam nas articulações, causando 
inflamação. Além disso, as células B podem funcionar como células apresentadoras de 
antigénio e ativar células T, sendo também capazes de produzir citocinas uma vez ativadas 
e participar na organização de estruturas linfóides secundárias. A descoberta da eficácia da 
terapêutica de depleção de células B com rituximab (RTX) trouxe não só melhorias na 
qualidade de vida dos doentes, como também veio reforçar a posição-chave destas células 
nesta doença autoimune. 
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O principal objetivo deste trabalho foi a caracterização das subpopulações de células B no 
sangue periférico de doentes com AR em fase inicial, sem terapêutica e em doentes com AR 
estabelecida. Adicionalmente, de forma a analisar as possíveis influências do tratamento no 
desenvolvimento dos processos imunológicos mediados pelas células B na evolução da AR, 
foi também comparado o efeito dos diversos tratamentos (MTX, anti-TNF e TCZ) no fenótipo 
das células B e na produção de citocinas e quimiciocinas diretamente relacionadas com a 
ativação de células B na AR. Para tal, foram incluídos neste estudo, um grupo de doentes 
com poliartrite não tratada (n=13) com menos de 1 ano de duração da doença, os quais 
foram classificados como AR iniciais (ERA). Foram também analisados doentes com AR 
estabelecida sob terapêutica com MTX (MTX, n=17) e MTX pré-biológico (MTX pre-bio, 
n=29). Dentro do grupo MTX pre-bio, foi realizada uma segunda colheita de sangue em 
doentes com AR oito meses após terem iniciado tratamento com anti-TNF (n=10) ou TCZ 
(n=7). 
A análise da frequência das subpopulações das células B no sangue periférico foi efetuada 
usando o sistema de classificação IgD/ CD27 que permite a identificação das principais 
quatro subpopulações de células B (CD19+): naïve (IgD+CD27-), pre-switch-memory 
(IgD+CD27+), post-switch memory (IgD-CD27+) e double-negative (DN, IgD-CD27-). De 
forma a poder identificar e caracterizar a subpopulação de plasmócitos no sangue periférico, 
foi usado o sistema de classificação IgD/ CD38, que identifica os plasmócitos como IgD-
CD38++, dentro da região das células B CD19+. 
 
Neste estudo não foram observadas diferenças nas células B totais (CD19+) nos doentes 
com AR em comparação com os controlos saudáveis. Contudo, quando analisadas as 
subpopulações de células B, foram observadas alterações nas células B de memória em 
circulação, nomeadamente um aumento da subpopulação de células B de memória DN 
(IgD-CD27-) nos doentes com AR estabelecida tratados com MTX e MTX pré-biológico, em 
relação aos controlos saudáveis. 
 
De modo a caracterizar o fenótipo das células B na fase inicial e estabelecida da AR, foram 
estudados vários marcadores celulares diretamente relacionados com a ativação e 
sobrevivência de células B (BAFF-R, TACI e BCMA), ativação celular (HLA-DR, CD69 e 
CD86), ativação mediada pelo recetor de células B (IgM), diferenciação (CD5), quimiotaxia 
das células B (CXCR5), apoptose mediada pelo complexo Fas (CD95) e ativação mediada 
pelo Toll-like receptor 9 (TLR9), através da análise da intensidade média da fluorescência 
(MFI). Adicionalmente, foram quantificados no soro de todos os grupos analisados os níveis 
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de CXCL13, uma quimiocina importante para as células B, e o CD23 solúvel (sCD23), 
envolvido na maturação das células B. 
 
O BAFF, uma citocina fundamental na sobrevivência das células B, tem sido sugerida como 
potencial alvo terapêutico para doenças autoimunes dependentes de células B, como a AR. 
Esta citocina apresenta 3 recetores: BAFF-R, TACI e BCMA. Neste estudo observou-se um 
aumento da MFI do TACI em doentes com AR estabelecida sob terapêutica com anti-TNF, 
em particular na subpopulação de células B post-switch memory. Nos restantes recetores do 
BAFF não foram encontradas diferenças significativas em comparação com os controlos 
saudáveis. O recetor TACI tem uma função ambígua, pois pode funcionar como recetor de 
ativação e/ ou de inibição das células B. É possível que o tratamento com anti-TNF induza 
um aumento da expressão de TACI nas células B de modo a inibir a sua ativação e o 
desenvolvimento da autoimunidade. 
 
Estudos anteriores têm evidenciado que as células B, uma vez ativadas, aumentam a 
expressão de marcadores de ativação como o HLA-DR, CD69 e CD86. Neste trabalho, 
embora não tenham sido observadas diferenças na MFI do CD69 e CD86 nas 
subpopulações de células B analisadas nos grupos de doentes em comparação com os 
controlos saudáveis, foi encontrado um aumento significativo na MFI do HLA-DR em 
doentes com AR estabelecida sob terapêutica com anti-TNF e TCZ. Estudos anteriores 
demonstraram que as terapêuticas com anti-TNF e TCZ diminuem a infiltração celular 
observada na membrana sinovial dos doentes com AR. É possível que, devido ao efeito da 
terapêutica, as células B ativadas que infiltram as articulações regressem ao sangue 
periférico, justificando deste modo o aumento da MFI do HLA-DR. Foi também observada 
uma diminuição da MFI do CD86 nos doentes com AR estabelecida tratados com anti-TNF e 
TCZ em comparação com as colheitas baseline, o que sugere uma inibição da ativação das 
células B induzida pelo tratamento com imunosupressores. 
 
A apoptose por meio do recetor de morte celular Fas (CD95) desempenha um papel central 
na manutenção da auto-tolerância imunológica periférica. De facto, alterações nesta via de 
apoptose foram demonstradas na patogénese de doenças autoimunes como a AR. Neste 
estudo, valores aumentados de MFI do CD95 foram observados nas células B de memória 
post-switch em doentes com AR estabelecida após o tratamento com anti-TNF e TCZ 
quando comparados com controlos saudáveis, o que poderá ser uma consequência direta 
do tratamento como forma de neutralizar a ativação de células B autoreativas. 
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Estudos efetuados na AR e noutras doenças autoimunes têm revelado alterações nas 
células B CD5+. Estas células estão associadas à reabsorção óssea através da produção de 
IL-6, uma citocina que estimula a diferenciação de osteoclastos, as células responsáveis 
pela erosão óssea. Este marcador também tem sido sugerido como um regulador negativo 
da ativação de células B. Neste trabalho foi encontrada uma diminuição significativa da 
frequência de células B CD5+ em todos os grupos de doentes com AR estudados, em 
comparação com controlos saudáveis. A diminuição da frequência destas células em 
circulação em todos os grupos de doentes poderá ser resultante do recrutamento de células 
B CD5+ para a membrana sinovial, onde ocorre o principal processo inflamatório na AR, o 
que poderá contribuir para a erosão óssea. Além disso, foram observados aumentos dos 
valores de MFI do CD5 em doentes com AR estabelecida sob terapêutica com anti-TNF e 
TCZ, que poderão estar relacionados com a função inibitória deste marcador na ativação 
das células B. 
 
A estimulação de células B através de TLRs também pode ser um mecanismo diretamente 
relacionado com autoimunidade. O TLR9, em particular, tem sido associado ao 
desenvolvimento da AR. Sabe-se que a associação do BCR e TLR9 pode ativar as células B 
autoreativas que reconhecem o DNA CpG endógeno libertado a partir de células apoptóticas 
e o DNA-CpG IgG dos complexos imunes nas articulações com AR, e induzir a 
transformação das células B em plasmócitos produtores do FR. Neste estudo, a expressão 
aumentada de TLR9 foi observada em todas as subpopulações de células B nos doentes 
com AR estabelecida após o tratamento com TCZ quando comparados com os controlos 
saudáveis. Além disso, foram observados aumentos nos valores de MFI do TLR9 nas 
células B post-switch memory e células DN em doentes tratados com MTX em comparação 
com os controlos saudáveis. Estas observações sugerem que as células B podem ter 
mecanismos alternativos para perpetuar a autoimunidade, através da ativação mediada pelo 
TLR9.  
 
O CXCR5 é um recetor de quimiocina expresso nas células B de recirculação. Este recetor 
de quimiocina e o seu ligando, CXCL13, estão envolvidos na quimiotaxia de células B, 
estando regulados positivamente no líquido sinovial dos doentes com AR. Neste estudo, foi 
observado um aumento dos níveis de expressão (MFI) do CXCR5 nas células B e um 
aumento dos níveis séricos de CXCL13 em doentes com AR quando comparados com 
controlos saudáveis, o que pode indicar uma regulação positiva da quimiotaxia de células B 
na AR e o seu recrutamento para os locais de inflamação, como as articulações. 
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Durante a ativação de células B, o CD23 membranar (mCD23) é clivado por uma protease 
associada à célula e libertado como CD23 solúvel (sCD23). Níveis aumentados de sCD23 
foram encontrados em doentes com AR, os quais estão diretamente relacionados com a 
erosão das articulações. Neste estudo, o aumento dos níveis séricos de sCD23 detetados 
em doentes ERA não tratados em comparação com os controlos saudáveis, poderá indicar 
uma ativação precoce das células B desde a fase inicial da doença. 
 
Em conclusão, os resultados desta tese suportam a existência de alterações nas células B 
de memória em circulação na fase estabelecida da AR. Além disso, os níveis de expressão 
de marcadores celulares podem ser afetados pelos tratamentos com anti-TNF e TCZ, 
nomeadamente marcadores de ativação (HLA-DR, CD86). Doentes na fase inicial da 
doença, sem terapêutica apresentam diminuições significativas nas frequências de células B 
CD5+, expressão elevada de CXCR5 e níveis elevados de CXCL13 e sCD23 no soro em 
comparação com os controlos saudáveis, o que suporta a hipótese da ativação das células 
B e o seu envolvimento na patogénese e desenvolvimento da AR desde a fase inicial da 
doença.  
 
Palavras-chave: Artrite Reumatoide, Células B, Marcadores celulares, Metotrexato, Anti-
TNF, Tocilizumab  
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ABSTRACT 
 
Rheumatoid arthritis (RA) is a systemic inflammatory autoimmune disease characterized by 
chronic pain and progressive joint damage. The etiology of RA is unknown and the disease 
prevalence in the adult population is 0.5-1% worldwide. If left untreated, RA leads to joint 
destruction, functional disability, comorbidity and reduced life expectancy.  
Different effector pathways and cells are involved in the cascade of events leading to the 
progression and persistence of the disease. B cells play critical roles in RA physiopathology 
through diverse mechanisms. B cells produce autoantibodies such as rheumatoid factor (RF) 
and anti-citrullinated protein antibodies (ACPA), which form immune complexes that deposit 
in the joints, causing inflammation. Additionally, B cells can function as antigen presenting 
cells and activate T cells; release cytokines once activated and participate in ectopic 
lymphoid organogenesis. 
The main goal of this work was to characterize B cell subpopulations in the peripheral blood 
from untreated early rheumatoid arthritis (ERA) patients and established treated RA patients. 
A full characterization of peripheral blood B cell subpopulations, serum cytokine and 
chemokine environment was performed. 
 
It was found that established RA patients have disturbances in the frequencies of memory B 
cell subpopulations in circulation, namely a significant increase in double negative IgD-CD27- 
B cells. Also, the expression levels of cellular markers can be affected by TNF inhibitors and 
TCZ treatment, particularly activation markers (HLA-DR, CD86). Furthermore, untreated ERA 
patients have significantly decreased frequencies of CD5+ B cells, elevated CXCR5 
expression and higher serum CXCL13 and sCD23 levels in comparison with controls, which 
support an early B cell activation in RA pathogenesis.  
In conclusion, alterations in the mechanisms associated with B cells’ physiopathology are 
observed since early RA that might be modulated by treatment with TNF inhibitors and TCZ 
at later stages of the disease. 
 
Keywords: Rheumatoid Arthritis, B cells, Cellular markers, Methotrexate, TNF-inhibitors, 
Tocilizumab 
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I. INTRODUCTION 
 
1. Rheumatoid Arthritis 
1.1. Definition 
Rheumatoid arthritis (RA) is a systemic inflammatory autoimmune disease characterized by 
chronic pain and progressive joint damage. The disease prevalence in the adult population is 
0,5-1% worldwide. RA onset usually occurs between 30-50 years of age and it is more 
frequent in women, suggesting a specific hormonal component association. RA is associated 
with a high risk of functional disability, a diminished quality of life and increased mortality 
when compared to healthy individuals [1, 2]. Risk factors such as smoking, infectious agents 
(e.g., Epstein-Barr virus, cytomegalovirus) and their products, environment, obesity can 
contribute to a worse prognosis [2, 3]. 
In general, RA is clinically recognized as an inflammatory process affecting joints, but the 
presence of extra-articular manifestations makes it a systemic disease with different clinical 
patterns. RA affects mainly the small joints such as those of the hands, wrists and feet and, if 
not properly treated, leads to bone and cartilage destruction with complete loss of joint 
integrity [1, 2]. RA is responsible for high levels of functional impairments: 20 to 30% of 
people with RA become permanently work-disabled within three years of diagnosis and 50% 
after ten years [4-6]. 
For years, RA diagnosis was established according to the 1987 American College of 
Rheumatology (ACR) criteria [7] and at least four of the criteria had to be present for a 
positive classification as RA. Morning stiffness lasting at least 45 minutes, fatigue and 
symmetrical inflammation of large and small joints are the most common initial symptoms of 
RA. Recently, RA diagnosis is defined according to the 2010 ACR/ European League 
Against Rheumatism (EULAR) classification criteria (appendix 1) [8, 9]. 
 
1.2.  Etiology and pathophysiology 
The etiology of RA is unknown. Different effector pathways and cells are involved in the 
cascade of events leading to the progression and persistence of the disease [1, 10, 11].  
The inflammatory process in RA synovium (Figure 1) is initiated when an unknown antigenic 
trigger induces the development of an inflammatory autoreactive response. Antigen-
presenting cells (APCs) exhibit antigenic processed peptides to T cells, interacting through 
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the major histocompatibility complex (MHC) – T-cell receptor (TCR) and costimulatory 
signals via CD28-B7 family receptor CD80/86 [12, 13]. 
 
 
 
 
 
 
 
 
 
Figure 3. Representative scheme illustrating the differences between healthy (a) and rheumatoid joints (b). Adapted from[14]  
 
B cells can function both as antibody producing cells and as efficient APCs[15]. In RA, 
autoreactive B cells produce autoantibodies such as rheumatoid factor (RF) and anti-cyclic 
citrullinated peptides (anti-CCP)[16], which are able to form immune complexes that deposit 
in the joints[16, 17]. These immune complexes activate monocytes through the low-affinity 
IgG receptor FcγRIIIa, leading to the production and release in synovial tissue of several 
proinflammatory cytokines such as tumor necrosis factor (TNF)[17], interleukin (IL)-1β and 
IL-6[18]. Activated synovial fibroblasts promote the expression of cell-adhesion molecules 
such as VCAM1 that contribute to an increase of cellular infiltration in the joints[19]. 
Additionally, the local production of metalloproteinases (MMP) such as MMP3 or MMP9, as 
well as the production of receptor activator for nuclear factor κB ligand (RANKL) increases 
cartilage and bone destruction [20, 21]. The inflamed synovial membrane begins to grow 
irregularly, forming invasive “pannus” tissue, which consequently invades and destroys 
cartilage and bone. RA pannus is mainly composed by mononuclear cells and fibroblasts. 
The inflammatory process is mediated by the activation of intracellular signaling pathways 
that stimulate the production and the release of multiple cytokines, chemokines, grow factors, 
proteinases and adhesion molecules that further increase joint erosion. In late-stages of RA, 
the pannus becomes fibrotic, minimally vascularized, with collagen fibres overlying articular 
cartilage [21-24]. 
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1.3. Genetic predisposition and environmental risk factors 
Rheumatoid Arthritis involves a complex interplay between environmental and genetic risks 
factors [25]. Heritability studies suggest that 60% of predispositions to RA are explained by 
genetic factors, leaving the remaining 40% to environmental and stochastic factors [25-27].  
The genetic association in RA is due to the histocompatibility leucocyte antigen (HLA) DR 
genes, which reside in the MHC and participate in antigen presentation [28-30]. The risk for 
developing RA is related to the presence of specific alleles of the class II gene HLA-DRB1 
[31] that encode a conserved sequence of aminoacids, the shared epitope (SE), in the third 
hypervariable region (HVR3) of the class II DRβ1 chain [30, 31]. This sequence is found in 
multiple RA-associated DR genes, including DR1, DR4, and DR14. The location of SE on 
MHC molecules suggests that it might have a role on the ability of HLA-DR to bind and 
present specific arthritogenic peptides, which might cause RA. In inflamed joints, MHC class 
II-dependent T cell activation by APCs (B cells, monocytes, dendritic cells) is considered a 
major driver of the disease, which reinforces the relevance of adaptive immunity in RA 
pathogenesis [28-31]. 
The environmental risk factors in RA include female gender, age, a previous family history of 
RA, smoking, obesity and some infectious agents [3, 32-35]. 
The best established environmental factor for RA is smoking. A study that included 13 
monozygotic twin pairs discordant for RA and smoking, revealed that the smoker was the 
one who developed the disease in 12 out of 13 pairs [36]. Furthermore, additional studies 
have also indicated an association between smoking and autoantibody production, namely 
with anti-citrullinated protein antibodies (ACPA). The observation that RA associated 
autoantibodies RF and ACPA may be present for more than 10 years before disease onset 
suggests that risk factors are active several years prior to the development of the disease 
[26, 33, 36, 37]. 
Infectious agents such as Epstein-Barr virus [3], cytomegalovirus [38], Proteus species [39], 
Mycobacterium tuberculosis [40], parvovirus B19 [41], Escherichia coli and their products 
(e.g. heat-shock proteins (HSP)) [42] can also be considered risk factors. These associations 
have been supported by increased antibody titers against the infectious organism present in 
RA patients and the possibility of molecular mimicry [3, 38-42]. 
 
1.4. Prognosis and treatment 
In early stages of RA, predictors such as high functional impairment, early involvement of 
several joints, high erythrocyte sedimentation rate or C-reactive protein levels at disease 
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onset, positivity for autoantibodies (RF, ACPA) [37, 43] and early radiographic changes can 
be related to a worse disease prognosis. The presence of specific alleles that encode the 
susceptibility epitope on MHC molecules might also influence the severity of the disease, 
since the risk of extra-articular and erosive disease is greater if the patients are homozygous 
[28, 44]. An adequate RA treatment is most important for the patient and the society. 
Uncontrolled active RA causes disability, decreased quality of life, and increases 
comorbidity, which results in loss of employment, high medical and social costs, and 
substantial morbidity and mortality. This impact of RA ultimately justifies expensive treatment 
[5, 25]. Although no cure has been found for RA, it is clear that establishing a diagnosis as 
early as possible and immediate treatment are the basis for a successful management of 
these patients [25].  
The main goals of RA treatment are the preservation of function and quality of life, 
minimizing pain and inflammation, remission of symptoms and control of systemic 
manifestations [24, 45-48] 
Treatment options are divided in three main classes: 1) nonsteroidal anti-inflammatory drugs 
(NSAIDs); 2) corticosteroids; and 3) disease modifying anti-rheumatic drugs (DMARDS) 
(synthetic and biological) [49, 50]. 
NSAIDs are efficient in relieving RA symptoms, but ineffective in the disease course. 
Corticosteroids are suppressors of the inflammatory response and previous studies have 
confirmed that are able to decrease the progression of the RA [51-54].  
DMARDs have demonstrated efficiency in managing disease activity by the suppression of 
the inflammation [55, 56]. Synthetic DMARDs such as methotrexate (MTX) [57], leflunomide, 
sulfasalazine and hidroxychloroquine are widely used in RA and have proven to be highly 
beneficial in decreasing inflammation and joint damage [58]. Combinations of DMARDs have 
also proven efficiency [59-61]. Nevertheless, despite being treated some patients still have 
persistent disease activity and often present side effects such as gastrointestinal and 
pulmonary toxicity, headaches, fatigue and less commonly bone marrow suppression [58]. In 
these cases, when patients do not respond favorably to synthetic DMARDs, treatment with 
biologic DMARDs must be initiated (Figure 2).  
TNF-inhibitory agents are the first line biologic treatment. Infliximab [62, 63], certolizumab 
[64], adalimumab and golimumab are monoclonal antibodies that target and neutralize 
circulating and synovial TNF [60]. Etanercept is a fusion protein that functions as a decoy 
receptor that binds to TNF and lymphotoxin (LT) family members)[50, 65]. Studies have 
shown that monotherapy with these drugs is effective [60]. Other biological agents include 
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abatacept, a fusion protein composed of the Fc region of IgG1 fused to the extracellular 
domain of cytotoxic T-lymphocyte antigen (CTLA)-4 that binds to the CD80/ CD86 molecule 
and [66, 67] inhibits T cell activation; tocilizumab, an IL-6 receptor antibody antagonist [18, 
68]; and anakinra, an IL-1 receptor antagonist that has only a moderate therapeutic effect 
[69]. 
Additionally, RA treatment can also be achieved with rituximab (RTX), a monoclonal antibody 
that selectively depletes B cells. RTX is chimeric monoclonal IgG1 anti-CD20 antibody 
whose efficiency in RA treatment has brought a new interest to the role of B cells in RA 
pathogenesis [70-73]. 
Figure 2. Summary of biologic treatments used in rheumatoid arthritis. Adapted from [74] 
 
2. B cells  
2.1 Origin, development and function 
B lymphocytes are white blood cells (6-10µm) whit a dense nucleus and little cytoplasm that 
express a membrane-bound Ig and originate and mature in the bone marrow. In humans, B 
cells correspond to 5-15% of total lymphocytes (2X102). These cells are important mediators 
of humoral immune response, by producing and secreting proteins called immunoglobulins 
(Ig) or antibodies. B cells can also function as APCs and secrete cytokines that can further 
activate T cells and contribute to the development of an effective immune response [75, 76]. 
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In humans, during fetal development, B cells are generated in the fetal liver and after birth, 
bone marrow assumes this function and continues throughout life. B cells arise from a 
lymphoid stem cell in the bone marrow and precede through several maturation stages, 
during which they express different cell surface markers. The B cell progenitor (pro-B cell) is 
the earliest distinctive B-lineage maturation stage. Pro-B cells proliferate in the bone marrow 
and differentiate into precursor B cells (pre-B cells). Pre-B cell stage is followed by an 
immature B cell stage that is not fully functional. B cells leave the bone marrow as naïve B 
cells when maturation is achieved by co-expression of IgM and IgD on their surface [75, 77-
81]. The B cell differentiation stages in the bone marrow correspond to the antigen-
independent phase of B cell development [81, 82]. Once they leave the bone marrow, naïve 
B cells, which have never encountered an antigen, circulate in the blood and lymphatic 
systems and are carried to secondary lymphoid organs (lymph nodes, spleen, Peyer’s 
Patches), where they further differentiate. After encountering an antigen, naïve B cells 
transform into large B-blasts and may follow two different pathways. Some cells proliferate 
and differentiate into short-living IgM producing plasma cells and a minority of B-blasts will 
differentiate to form germinal centers (GC) [82]. In GC reactions, B cells differentiate either 
into memory B cells or plasma cells (Figure 3).  
Figure 3: B cells development adapted from [83] 
 
Since an antigen is required for B cell activation and differentiation in the periphery, this 
stage comprises the antigen-dependent phase of B cell development. In the absence of 
antigen-induced activation, naïve B cells in the periphery become apoptotic [84]. 
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2.2. Antibodies 
Antibodies, also called immunoglobulins, are the antigen-binding proteins secreted by 
plasma cells, present on the B cell membrane or in circulation. Antibodies can eliminate 
pathogens by several mechanisms such as opsonization, complement activation and direct 
lysis of bacteria and/or neutralization of virus and toxins to prevent their entry into host cells 
[77, 84]. An antibody molecule has a common structure of four peptide chains, two identical 
light (L) chains and two identical heavy (H) chains and has five major classes based on the 
diversity of their heavy chain, namely IgM, (µ), IgG (γ), IgA (α), IgD (δ) and IgE (ɛ), each one 
with different structural and functional properties [77, 85, 86]. Antibody diversity is achieved 
by V(D)J recombination (V-variable, D-diversity and J-joining), somatic hypermutation (SHM) 
and class or isotype-switching [84, 86].  
The V(D)J recombination is an ordered site-specific DNA rearrangement process that occurs 
in developing lymphocytes in the BM, in which V(D)J gene segments are randomly combined 
at recombination signal sequences (RSS) [84, 87]. RSS are recognized by an endonuclease 
coded by recombination activating gene (RAG)-1 and RAG-2, responsible for DNA double-
stranded breaks following the 12-23 bp rule [84, 86]. The diversity generated by this process 
is further increased by terminal deoxynucleotidyl transferase (TdT) that adds nucleotides to 
gene segments junctions [84, 86]. SHM is a mechanism that occurs within GC in secondary 
lymphoid organs and involves the introduction of point mutations, mainly nucleotide 
substitutions, as well as occasional deletions and duplications at a very high rate into the 
DNA of heavy and light chain variable region genes, at CDR [86]. This differential selection is 
due to an increase in antibody affinity for an antigen, a process known as affinity maturation. 
CSR is an isotype switching deletional DNA recombination process that occurs in mature B 
cells and consists of replacing an expressed heavy-chain constant-region gene, usually IgM, 
with another one of a different biological function – IgG, IgA or IgE [86]. During this process, 
only 10 the effector functions of the antibody are changed. SHM and CSR are mediated by 
activation-induced cytidine deaminase (AID) that promotes the recombination event [88-90]. 
 
3. B cells and rheumatoid arthritis 
For decades, RA was considered a T-cell driven disease. In the rheumatoid synovium, 
accumulation of CD4+ T lymphocytes suggested that macrophages could be activated by T 
cells, specifically T helper (Th)-1, to produce proinflammatory cytokines such as TNF, IL-1β 
and IFNγ [91-93]. 
In patients with RA, the increase of IL-17 levels in synovial fluid [94] suggests the 
involvement of Th17 cells and this association is directly proportional to the severity of joint 
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destruction [23, 95]. In fact, the percentage of Th17 cells is increased in RA synovial fluid 
[96]. These facts are supported by studies performed in animal models of arthritis that 
demonstrate that a local expression of Il-17 in mouse joints results in acute inflammation, 
while the incidence and severity of arthritis is markedly attenuated in IL-17-deficient mice [97, 
98]. Contrarily to Th1, Th2, and Th17 cells, regulatory T cells (Tregs) CD4+CD25+ are 
characterized by low proliferative capacity upon triggering the T cell receptor (TCR) and by 
their ability to suppress CD4+ and CD8+ T-cell immune responses [99]. Several studies have 
proposed that Tregs are severely impaired in autoimmune rheumatic diseases, suggesting 
that in fact a breakdown of Treg-mediaded peripheral tolerance may have occurred [99-101]. 
Despite all the observations that support a role for T cells in RA development, the 
disappointing results obtained with anti-CD4 therapy in humans reinforced the notion that 
perhaps other parts of the inflammatory process of RA should be better studied and 
understood [50, 102, 103]. 
Although the cause that triggers RA autoimmune process remains unknown, it has been 
demonstrated that several types of cells from both innate and adaptative immune system 
actively participate and form complex networks of cell-cell interactions that contribute to the 
development and chronicity of synovitis and inflamation on RA [104, 105]. Several studies 
have pointed to B cell function as a critical factor in the development of RA [85, 106-108]. In 
RA, B cells are responsible for the production of autoantibodies [109], which include 
antibodies against cartilage components (anti-type II collagen or anti-CII; anti-human 
cartilage glycoprotein 39 or anti-gp39); enzymes (anti-glucose-6-fosfato-isomerase or anti-
GPI, anti-enolase); nuclear proteins (anti-RA33) and stress proteins. RF and ACPAs are, 
however, the autoantibodies most specifically associated with this disease. RF are 
autoantibodies that directly bind to the Fc portion of normal human IgG and ACPAs are 
autoantibodies that recognize peptides or proteins containing citrulline, a non-standard 
aminoacid generated by the post-translational modification of arginine by peptidylarginine 
deiminase (PAD) enzymes, in a process known as citrullination. RF and ACPAs can form 
immune complexes that deposit in the joints, activate complement and cause inflammation 
[110]. The clinical usefulness of RF and ACPAs has been acknowledged due to their good 
diagnostic sensitivity and prognostic value, but the clinical significance and pathogenic roles 
of the other autoantibodies are unknown. Furthermore, the association between high titer of 
RF and worse prognosis indicate that RF may have an important role in the pathogenesis of 
RA, although there are RA patients seronegative for RF who also manifest the disease. 
Moreover, ACPAs-positive RA patients have a higher cellular infiltration in RA synovium and 
these autoantibodies are also helpful to predict the outcome of patients with undifferentiated 
arthritis [37, 109, 111]. 
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B cells are also very efficient APCs that activate T cells through the expression of 
costimulatory molecules [112, 113]. A B cell is considered autoreactive when its B cell 
receptor (BCR) targets a self-antigen. In RA, B cells have the ability to present processed 
self-antigens to T cells, thus allowing the development of an autoreactive immune response. 
Indeed, RF+ B cells play an important role in antigen presentation and in the induction of T 
cell activation [12, 114, 115].  
B cells can also function as cytokine and chemokine-producing cells that promote leukocyte 
infiltration in the joints and the formation of ectopic lymphoid structures [116, 117], thus 
aggravating angiogenesis and synovial hyperplasia [15, 118].  
The efficacy of B cell depletion therapy with RTX reinforced the relevance of B cells in RA 
pathogenesis [119]. 
 
 
 
 
II. AIMS 
 
The main goals of the present work were: 
  To characterize B cell subpopulations in the peripheral blood from untreated early 
rheumatoid arthritis (ERA) patients and established treated RA patients. 
 To analyze the cytokine and chemokine environment directly related with B cell 
activation since early RA. 
 To compare the effect of treatment options (methotrexate-MTX, TNF-inhibitors and 
tocilizumab-TCZ) on B cell phenotype and cytokine production in ERA and 
established RA patients.  
 
 
 
 
 10 
 
III. MATERIALS AND METHODS 
 
Patients  
Blood samples were collected from 13 consecutive patients with untreated polyarthritis 
(Rheumatology Department, Hospital de Santa Maria, Lisbon) of < 1 year disease duration. 
After a minimum follow-up of 3 months, the patients fulfilled the 2010 ACR/ EULAR criteria 
for RA and were classified as early RA (ERA). In addition, blood samples from 17 patients 
with established RA treated with methotrexate (MTX); 29 patients with established RA 
treated with MTX before starting biologic DMARD therapy (MTX pre-biologic, MTX pre-bio); 
10 patients under treatment with TNF inhibitors and 7 patients under tocilizumab (TCZ) 
treatment were also collected for comparison (Rheumatology Department, Hospital de Santa 
Maria, Lisbon). Furthermore, blood samples from 15 healthy donors were also collected and 
processed for comparison. 
This study was approved by the local ethics committee (Comissão de Ética do Hospital de 
Santa Maria), and all patients and healthy donors signed an informed consent form. Patient 
care was conducted in accordance with standard clinic practice, and the study was 
performed in accordance with the Declaration of Helsinki (2008). 
 
Isolation of peripheral blood mononuclear cells  
Peripheral blood mononuclear cells (PBMC) were isolated from 40 ml heparinized whole 
blood following density gradient centrifugation with Ficoll-Paque Plus (GE Healthcare, 
Sweden).Cells were washed twice in 1X phosphate buffered saline (PBS) and cellular 
viability was estimated with 0.4% Trypan blue (Sigma, USA). 
 
Flow Cytometry 
Immunophenotyping of B cells was performed in PBMC samples (1X106 cells/ sample) using 
matched combinations of anti-human murine monoclonal antibodies (mAbs) conjugated to 
FITC,  phycoerytrin (PE), peridinin chlorophyll protein (PerCP)-Cy5.5, allophycocyanin 
(APC), PE-Cy7, eFlour 450 and APC-eFluor780.Combinations of anti-CD19 conjugated to 
PerCP-Cy5.5 or APC, anti-IgD conjugated to PE-Cy7 or FITC, anti-CD27 conjugated to 
eFluor450 or FITC, anti-CD38 conjugated to APC-eFluor780, anti-BAFF-R conjugated to PE, 
anti-TACI conjugated to APC, anti-CD86 conjugated to PE, anti-CD69 conjugated to PerCP 
or APC, anti-IgM conjugated to PE, anti-CD5 conjugated to APC, anti-CXCR5 conjugated to 
 11 
 
PE, anti-HLA-DR conjugated to APC, anti-CD95 conjugated to APC, anti-BCMA conjugated 
to PE and anti-TLR9 conjugated to APC were used. All antibodies were purchased from BD 
Pharmingen (USA), eBioscience (USA) and R&D Systems (United Kingdom). For cell 
surface stainings, PBMC were incubated with antibodies during 30 minutes, in the dark, at 
4ºC. For TLR9 intracellular staining, PBMC were fixed during 20 minutes at room 
temperature with IC Fixation Buffer (eBioscience, USA), permeabilized with 1X 
Permeabilization Buffer (eBioscience, USA) and stained according to eBioscience 
intracellular antigen staining protocol. A total of 50.000 cells/ sample gated in CD19+ B cells 
were acquired with LSR Fortessa (BD). Data were analyzed with FlowJo (TreeStar, Stanford 
University, California, USA). All samples were acquired on the same day of the staining 
protocol. 
 
ELISA  
The B-lymphocyte chemoattractant (BLC) also known as C-X-C motif chemokine 13 
(CXCL13) and the soluble form of CD23 (sCD23) were quantified in serum samples from all 
groups by enzyme-linked immunosorbent assay (ELISA) (R&D systems, United Kingdom), 
according to the manufacturer’s instructions. Samples were analyzed using plate reader 
Infinite M200 (Tecan, Switzerland). 
 
Statistical analysis 
Statistical differences were determined with GraphPad Prism (GraphPad, San Diego, USA). 
For populations that did not follow a Gaussian distribution, non-parametric tests were used. 
The Mann-Whitney test was used for comparisons between 2 independent groups. For 
comparisons between 3 or more groups, the Kruskal-Wallis and Dunn’s multiple comparison 
tests were used. The Wilcoxon matched pairs test was used for comparisons between 2 
paired groups. Correlation analyses were performed using Spearman’s test. Differences 
were considered statistically significant for p < 0.05. 
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IV. RESULTS 
 
1. Clinical characterization of patients 
A group of untreated polyarthritis patients (n=13) with less than 1 year of disease duration 
and classified as early RA (ERA) according to the 2010 ACR/ EULAR criteria after a 
minimum follow-up of 3 months was included in this study. ERA patients had a mean ± 
standard deviation age of 58±14 years old, 85% were female, 69% were RF positive, 62% 
were anti-CCP positive and DAS28 score was 4.1±2.0. A group of established RA patients 
under MTX treatment (n=17) with a mean age of 55±14 years old, 81% female and a DAS28 
of 2.5±1.2 was also included. Furthermore, a group of established RA patients under MTX 
treatment pre-biological therapy (MTX pre-bio, n=29) with a mean age of 57±11 years old, 
83% female and a DAS28 of 5.1±1.3 was also analyzed. From the MTX pre-bio group, a 
second blood collection was performed to RA patients that had either initiated treatment with 
TNF-inhibitors (n=10) or with tocilizumab (TCZ) (n=7), after an average follow-up of 8 months 
of treatment. In addition, blood samples were collected from age and sex-matched healthy 
donors (n=15). The clinical information and data from all patients and healthy controls 
included in this study is indicated in Table 1. 
 
Table 1. Clinical information of untreated ERA and established RA patients treated with MTX, MTX pre-bio, TNF 
inhibitors or TCZ. 
 Controls 
(n=15) 
ERA 
(n=13) 
MTX 
(n=17) 
MTX pre-bio 
(n=29) 
TNF 
(n=10) 
TCZ 
(n=7) 
Age (years) 52±7 58±14 55±14 57±11 56±15 61±10 
Sex (% female) 73 85 81 83 80 83 
Disease duration  (years) NA ≤ 1 7±6 13±12 14±13 8±4 
CRP (mg/dl) ND 1.4±2.1 0.5±0.6 1.1±1.2 1.9±2.5 0.1±0.1**#& 
ESR (mm/1
st
 hour) ND 44±26 23±22 32±22 47±39 6±5**#& 
VAS NA 40±33 38±34# 69±21 62±21 63±13 
DAS28 NA 4.1±2.0 2.5±1.2# 5.1±1.3 4.2±1.5 2.3±0.7# 
Swollen joints NA 4±4 1±2# 7±6 2±3 1±1 
Tender joints NA 5±5 2±3# 10±8 6±5 1±1# 
RF (+) % ND 69 77 74 78 50 
Anti-CCP (+) % ND 62 63 68 38 67 
ERA - Early Rheumatoid Arthritis; RA - Rheumatoid Arthritis; CRP - C-reactive protein; ESR - Erythrocyte Sedimentation Rate; 
VAS – Visual Analogue Scale; DAS28 – Disease Activity Score of 28 joints; RF – Rheumatoid Factor; Anti-CCP – anti-cyclic 
citrullinated peptide; NA – not applicable; ND – not determined.  Values are represented as mean ± standard deviation.  
** p < 0.05 in comparison with ERA   # p < 0.05 in comparison with MTX pre-bio  & p < 0.05 in comparison with TNF 
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2. Classification of B cell subpopulations 
To analyze the frequency of B cell subpopulations in the periphery, B cells were classified 
using the IgD/ CD27 classification system that allows the identification of four main B cell 
subsets (gated in CD19): naïve B cells (IgD+CD27-), pre-switch-memory (IgD+CD27+), post-
switch memory (IgD-CD27+) and double-negative (DN, IgD-CD27-) B cells (appendix 2). A 
second classification system based on IgD/ CD38 (gated in CD19) was also used to identify 
circulating plasmablasts, defined as IgD-CD38++. The IgD/ CD38 classification system 
allows the identification of six B cell subpopulations: transitional (IgD+CD38++), naïve B cells 
(IgD+38+), IgD+ memory (IgD+CD38-), resting memory (IgD-CD38-), post-GC memory (IgD-
CD38+) B cells and plasmablasts (IgD-CD38++) (appendix 2). Although an analysis with both 
classification systems has been performed in the present work to define B cell 
subpopulations, the results presented in this thesis are based on IgD/ CD27 classification 
system (except plasmablasts) in order to compare with previous results obtained by our 
group in which IgD/ CD27 classification was used [120]. 
 
 
2.1. Established RA patients have alterations in the frequency of memory B cell 
subpopulations in peripheral blood 
The analysis of the frequency of total CD19+ B cells has revealed that no significant 
differences were found in ERA and established RA patients treated with MTX, MTX pre-bio, 
TNF inhibitors or TCZ when compared to healthy controls. However, when analyzing B cell 
subpopulations, it was observed that established RA patients treated with MTX and MTX pre-
bio had significantly increased frequencies of DN (IgD-CD27-) B cells in comparison to 
controls (p < 0.05). Furthermore, no significant differences were observed in the remaining B 
cell subpopulations analyzed (naïve, pre-switch memory and post-switch memory B cells) in 
all groups (Figure 4). Importantly, no significant correlations were found between the 
frequencies of all B cell subpopulations with age or with disease activity (DAS28) in all 
groups studied (data not shown). 
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Figure 5. Frequency of B cell subpopulations in ERA and established RA patients treated with MTX, MTX pre-bio, TNF 
inhibitors and TCZ in comparison with healthy controls. Lines represent median percentage values.  
* p < 0.05 in comparison with Controls. 
 
 
3. B cell markers and effect of treatment in comparison with healthy controls 
In this study the expression of several cellular markers was analyzed by mean fluorescence 
intensity (MFI) to characterize B cell phenotype in circulation in untreated early and 
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established treated RA patients, according to their function. Thus, BAFF-R, TACI and BCMA 
were studied to analyze the expression of BAFF receptors on B cells; CD69, CD86 and HLA-
DR were studied to analyze B cell activation; CXCR5 was studied to analyze B cell 
chemotaxis; CD95, also known as Fas receptor (FasR), was studied to analyze Fas-
mediated apoptosis; IgM was analyzed as a component of the BCR; CD5 was studied to 
analyze B cell differentiation and TLR9 was studied to analyze the main TLR expressed by B 
cells. The MFI values obtained for all cellular markers were considered in all B cell 
subpopulations, except in plasmablasts (IgD-CD38++), due to the low number of events 
obtained during data acquisition and analysis.  
 
 
3.1. TACI expression increases on memory B cell subpopulations after treatment with 
TNF inhibitors, but no changes occur in BAFF-R and BCMA MFI values in all B cell 
subsets 
B cell activating factor (BAFF) is an important cytokine for B cell activation and survival [108, 
121, 122] that binds to three receptors: BAFF-R, TACI and BCMA. While no significant 
differences were found in BAFF-R (Table 2) and BCMA (Table 3) MFI levels in all groups 
analyzed in all B cell subpopulations, TACI MFI was significantly increased in total CD19+ B 
cells in established RA patients after treatment with TNF inhibitors in comparison with 
controls, namely in post-switch memory (p = 0.0170) and double negative B cells (p = 
0.0084) (Table 4). Furthermore, TACI MFI levels were also significantly increased in double 
negative B cells of ERA patients when compared to controls (p = 0.0138).. Moreover, no 
significant differences were observed in the frequencies of BAFF-R+ B cells in all B cell 
subpopulations in all groups analyzed (data not shown). 
 
Table 2. MFI values of BAFF-R on B cell subpopulations. Represented values are mean ± standard deviation (SD). 
 Controls ERA MTX MTX pre bio TNF TCZ 
CD19+  2012±1616 1602±1131 1793±1557 2457±1799 2702±1373 1813±1235 
NaÏve (IgD+27-) 1897±1763 1580±1148 1826±1589 2482±1868 2643±1373 1822±1314 
Pre-switch memory (IgD+27+) 2118±1779 1751±1190 2087±1763 2392±1839 2839±1430 1930±1232 
Post-switch memory (IgD-27+) 1901±1457 1602±1122 1736±1550 2388±1751 2823±1486 1523±1140 
DN (IgD-27-) 2045±1491 1589±1143 1656±1446 2475±1909 2571±1449 1498±1230 
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Table 3. MFI values of BCMA on B cell subpopulations. Represented values are mean ± SD. 
 Controls ERA MTX MTX pre bio TNF TCZ 
CD19+ 13±131 26±78 44±112 105±108 58±124 30±95 
NaÏve (IgD+27-) 29±33 5±27 34±126 30±92 29±153 7±36 
Pre-switch memory  (IgD+27+) 24±207 98±122 83±202 139±158 70±137 40±154 
Post-switch memory (IgD-27+) 109±109 131±57 122±75 169±75 131±61 136±139 
DN (IgD-27-) 81±88 111±57 111±74 127±64 103±65 102±112 
 
Table 4. MFI values of TACI on B cell subpopulations. Represented values are mean ± SD. 
 Controls ERA MTX MTX pre bio TNF TCZ 
CD19+ 181±309 321±394 222±276 202±297 400±249* 473±490 
NaÏve (IgD+27-) 219±425 231±352 153±298 178±350 344±250 452±562 
Pre-switch memory (IgD+27+) 381±288 546±452 462±335 374±449 733±629 928±1060 
Post-switch memory (IgD-27+) 178±217 459±415 264±374 275±380 486±287* 410±358 
DN (IgD-27-) 137±208 464±373* 333±289 285±357 415±209* 305±88 
 
* p < 0.05 in comparison with Controls 
 
3.2. TNF inhibitors and TCZ treatment increase the expression of the activation marker 
HLA-DR on B cells, but have no effect on CD69 and CD86 
In all groups studied, no significant differences were found in CD69 and CD86 MFI levels in 
all B cell subpopulations (Tables 5 and 6, respectively). Moreover, although no significant 
differences were observed in the frequencies of HLA-DR+ B cells in all groups (data not 
shown), alterations were found in HLA-DR MFI values in established RA patients treated with 
TNF inhibitors and TCZ in comparison with healthy controls and/ or in comparison with 
established RA treated with MTX pre-bio (Table 7). Indeed, it was observed that HLA-DR 
MFI values were increased in total CD19+ B cells, naïve, post-switch memory and DN B cells 
in established RA patients after treatment with TNF inhibitors in comparison with controls (p < 
0.05). After TCZ treatment, HLA-DR MFI values were increased in total CD19+ B cells, 
naïve, pre-switch memory and DN B cells (p < 0.05). Additionally, both TNF inhibitors and 
TCZ treatments induced a significant increase in HLA-DR MFI values in total CD19+ B cells 
when compared with MTX pre-bio group (p < 0.05). 
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Table 5. MFI values of CD69 on B cell subpopulations. Represented values are mean ± SD. 
 Controls ERA MTX MTX pre bio TNF TCZ 
CD19+ 78±127 8±43 42±112 86±131 27±42 55±66 
NaÏve (IgD+27-) 1±86 1±35 6±53 29±103 4±36 neg 
Pre-switch memory (IgD+27+) 246±262 69±58 215±241 184±200 171±216 207±270 
Post-switch memory (IgD-27+) 130±144 85±50 156±147 207±243 148±162 138±74 
DN (IgD-27-) 108±142 52±63 136±154 119±115 78±65 221±103 
 
 
Table 6. MFI values of CD86 on B cell subpopulations. Represented values are mean ± SD. 
 Controls ERA MTX MTX pre bio TNF TCZ 
CD19+ 69±136 65±66 111±143 144±102 67±136 95±69 
NaÏve  (IgD+27-) 48±124 12±110 38±152 13±227 13±131 16±95 
Pre-switch memory (IgD+27+) 84±184 116±102 161±144 148±175 132±172 98±183 
Post-switch memory (IgD-27+) 181±141 226±69 225±159 277±174 261±150 284±187 
DN (IgD-27-) 125±90 163±54 169±92 169±89 158±102 110±64 
 
 
Table 7. MFI values of HLA-DR on B cell subpopulations. Represented values are mean ± SD. 
 Controls ERA MTX MTX pre bio TNF TCZ 
CD19+ 25596±8709 32803±10483 26643±14333 23869±11973 38693±11768*# 43917±1848*# 
NaÏve (IgD+27-) 31834±13161 38098±12499 31259±17522 28832±14606 44972±14006* 54894±23771*# 
Pre-switch memory 
(IgD+27+) 
27497±13657 32426±9149 23627±10679 25547±13292 32238±12340 44302±21876* 
Post-switch 
memory  (IgD-27+) 
18012±6990 20544±6344 19199±10276 17262±8251 28359±7472*# 27368±15824 
DN (IgD-27-) 22010±9004 27647±9225 22382±12687 21495±10344 33234±11366* 35312±11773* 
 
* p < 0.05 in comparison with Controls                                                                      
# p < 0.05 in comparison with MTX pre-bio 
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3.3. CXCR5 expression is increased since early RA 
In all groups studied, no significant differences were found in the frequencies of CXCR5+ B 
cells in all B cell subpopulations (data not shown). Nevertheless, CXCR5 MFI values were 
significantly increased in total CD19+ B cells in ERA (p = 0.0276) and established RA 
patients after treatment with MTX and TNF inhibitors when compared to controls (p < 0.05) 
(Table 8). Moreover, it was observed that CXCR5 MFI values were significantly increased in 
naïve B cells in ERA and established RA patients treated with MTX, MTX pre-bio and TNF 
inhibitors in comparison with controls. 
 
Table 8. MFI values of CXCR5 on B cell subpopulations. Represented values are mean ± SD. 
 Controls ERA MTX MTX pre bio TNF TCZ 
CD19+ 3908±1896 5977±2423* 6380±3343* 5383±2556 7655±3352* 4958±2616 
NaÏve (IgD+27-) 4022±1993 6089±2354* 6746±3499* 6401±3101* 8173±4148* 5551±2598 
Pre-switch memory 
(IgD+27+) 
5794±2190 7001±2276 7576±3785 7058±2927 8882±4221 6449±2905 
Post-switch memory 
(IgD-27+) 
4401±2804 5203±2656 5212±3618 4675±2366 5962±2964 4101±2223 
DN (IgD-27-) 3480±2604 3539±1913 3693±2610 3088±1869 4088±2531 3448±2268 
 
* p < 0.05 in comparison with Controls                                                                      
 
 
3.4. CD95 expression increases on memory B cell subpopulations after treatment with 
TNF inhibitors and TCZ 
The analysis of the expression of CD95, a death receptor whose activation leads to 
apoptosis, revealed that no significant changes occur in CD95 MFI values on total CD19+ B 
cells in ERA and established RA patients irrespective of the treatment when compared to 
healthy controls. However, when analyzing B cell subpopulations, it was found that 
established RA patients treated with TNF inhibitors and TCZ have increased MFI values of 
CD95 in post-switch memory B cells in comparison to controls, but no significant differences 
where observed in the remaining B cell subsets (p < 0.05 ) (Table 9). 
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Table 9. MFI values of CD95 on B cell subpopulations. Represented values are mean ± SD. 
 Controls ERA MTX MTX pre bio TNF TCZ 
CD19 453±322 231±176 434±319 371±377 585±244 821±495 
NaÏve (IgD+27-) 313±438 123±263 179±318 99±219 372±224 549±489 
Pre-switch memory (IgD+27+) 672±339 644±304 791±426 528±396 1020±458 1052±425 
Post-switch memory (IgD-27+) 884±472 1005±470 919±796 981±740 2048±1693* 3243±2950* 
DN (IgD-27-) 548±314 587±332 589±342 580±551 796±346 926±641 
 
* p < 0.05 in comparison with Controls 
 
 
3.5. IgM expression and the frequency of IgM+ B cells in circulation in ERA and 
established RA patients is similar to controls 
In all groups of patients studied, no statistically significant differences were observed in the 
frequency of circulating IgM+ B cells (data not shown). Furthermore, no significant 
differences were found in IgM MFI values on total CD19+ B cells and all B cell 
subpopulations analyzed in all groups of patients when compared to healthy controls (Table 
10). 
 
Table 10. MFI values of IgM on B cell subpopulations. Represented values are mean ± SD. 
 Controls ERA MTX MTX pre bio TNF TCZ 
CD19 70±253 111±115 157±212 175±175 152±187 65±188 
NaÏve (IgD+27-) 67±369 86±178 126±315 191±319 182±235 34±286 
Pre-switch memory (IgD+27+) 523±515 532±418 679±676 569±390 744±613 483±588 
Post-switch memory (IgD-27+) 74±71 56±51 55±47 91±49 66±37 39±36 
DN (IgD-27-) 65±34 46±25 47±46 70±39 40±29 43±25 
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3.6. ERA and established RA patients have alterations in the expression levels of CD5 
and in the frequency of circulating CD5+ B cells 
A significant decrease in the frequency of circulating CD5+ B cells was found in total CD19+ 
B cells, namely on naïve B cells, in all patients´ groups (ERA, established RA treated with 
MTX, MTX pre-bio, TNF inhibitors and TCZ) in comparison with controls (data not shown). 
However, the analysis of CD5 expression on B cell subpopulations has shown that both TNF 
inhibitors and TCZ treatment induce a significant increase in CD5 MFI values on pre-switch 
and post-switch memory B cells when compared to healthy controls (p < 0.05) (Table 10). 
Furthermore, significantly increased CD5 MFI values were also found on naïve B cells from 
TCZ treated RA patients in comparison with MTX and MTX pre-bio groups (p < 0.05). 
 
Table 11. MFI values of CD5 on B cell subpopulations. Represented values are mean ± SD. 
 Controls ERA MTX MTX pre bio TNF TCZ 
CD19+ 615±324 600±348 458±355 461±536 691±201 798±344 
NaÏve (IgD+27-) 671±382 569±367 483±392 561±607 847±415 1112±224*#& 
Pre-switch memory (IgD+27+) 695±360 1136±696 822±555 822±852 1530±1012* 1930±1290*# 
Post-switch memory (IgD-27+) 284±291 532±393 406±297 391±475 643±344* 609±417* 
DN (IgD-27-) 447±475 559±279 384±270 341±391 599±333 577±395 
 
* p < 0.05 in comparison with Controls                                 
# p < 0.05 in comparison with MTX pre-bio 
& p < 0.05 in comparison with MTX  
 
 
3.7. TLR9 expression increases after TCZ treatment, but not after MTX or TNF 
inhibitors 
A significant increase in TLR9 MFI values was found in total CD19+ B cells and all B cell 
subpopulations studied in established RA patients after treatment with TCZ in comparison 
not only with controls (p < 0.05), but also with MTX pre-bio group (p < 0.05) (Table 12). In 
addition, TLR9 MFI was significantly increased on post-switch memory and DN B cells in 
MTX treated patients when compared to controls. No significant differences were found in 
ERA or established RA patients treated with MTX pre-bio or TNF inhibitors in comparison 
with controls in all B cell subsets analyzed. 
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Table 12. MFI values of TLR9 on B cell subpopulations. Represented values are mean ± SD. 
 Controls ERA MTX MTX pre bio TNF TCZ 
CD19 3333±2104 3698±2759 6072±4023 3602±3751 5885±4692 11968±7361*# 
NaÏve (IgD+27-) 2900±1819 3143±2165 5207±3440 3417±3756 5473±4509 10051±7456*# 
Pre-switch memory  
IgD+27+) 
4833±3068 5135±3458 8340±5231 5516±6265 7239±5515 13837±8414*# 
Post-switch memory 
 (IgD-27+) 
3964±2373 4730±3544 6913±4226* 4826±5136 6904±5402 11160±5744*# 
DN (IgD-27-) 3231±1745 3913±2664 6347±4362* 4110±4603 5915±4918 10126±5732*# 
 
* p < 0.05 in comparison with Controls                                 
# p < 0.05 in comparison with MTX pre-bio 
 
4. B cell markers and effect of TNF inhibitors and TCZ treatment in comparison 
with baseline 
In order to understand the effect of treatment options before and after RA patients initiate 
treatment, a second blood collection was performed in established RA patients from MTX 
pre-bio group after a mean period of 8 months of treatment with TNF inhibitors (n=10) or TCZ 
(n=7). The MFI values of all cellular markers studied (BAFF-R, TACI, BCMA, HLA-DR, CD69, 
CD86, CXCR5, CD95, IgM, CD5 and TLR9) were analyzed after treatment and compared to 
baseline values. 
 
4.1. TNF inhibitors and TCZ treatment affect B cell expression levels of HLA-DR, CD86 
and CD95  
It was observed that both TNF inhibitors and TCZ treatments affected the expression levels 
of HLA-DR on B cells. In fact, it was found that after treatment with TNF inhibitors, the HLA-
DR MFI values were significantly increased in total CD19+ B cells (p=0.0273) and in all B cell 
subpopulations analyzed (p < 0.05) (Table 13). The same result was observed after 
treatment with TCZ in total CD19+ B cells, particularly in naïve B cells (p = 0.0313) (Table 
14). Furthermore, TNF inhibitors also induced a significant increase in CD95 MFI values in 
total CD19+ B cells (p = 0.0039) and in all B cell subpopulations studied (p < 0.05) (Table 
15). The expression of CD86 was also found to be significantly decreased in total CD19+ B 
cells (p =0.0371), namely on naïve B cells, after treatment with TNF inhibitors (Table 16). 
Moreover, no significant differences were observed in the MFI values of BAFF-R, TACI, 
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BCMA, CD69, CXCR5, IgM, CD5 and TLR9 cell markers in all B cell subpopulations after 
treatment with TNF inhibitors and TCZ (data not shown). 
 
Table 13. MFI values of HLA-DR on B cell subpopulations before and after TNF inhibitors. Represented values are 
mean ± SD. 
 Before TNF inhibitor After TNF inhibitor 
CD19 21399±9378 37743±11951* 
NaÏve (IgD+27-) 24916±12819 43676±14051* 
Pre-switch memory (IgD+27+) 22260±10619 31610±12821* 
Post-switch memory (IgD-27+) 16126±6740 27972±7759* 
DN (IgD-27-) 18895±7880 31763±10821* 
 
* p < 0.05 in comparison with established RA patients before TNF inhibitors 
Table 14. MFI values of HLA-DR on B cell subpopulations before and after TCZ. Represented values are mean ± SD. 
 Before TCZ After TCZ 
CD19 21118±13439 49510±15320* 
NaÏve (IgD+27-) 30610±18731 62972±18502* 
Pre-switch memory (IgD+27+) 27221±17445 50681±20332 
Post-switch memory (IgD-27+) 16649±11418 29879±17053 
DN (IgD-27-) 18435±11920 38846±23605 
 
* p < 0.05 in comparison with established RA patients before TCZ 
 
Table 15. MFI values of CD95 on B cell subpopulations before and after TNF inhibitors.  Represented values are mean 
± SD. 
 Before TNF inhibitor After TNF inhibitor 
CD19 203±263 639±182* 
NaÏve (IgD+27-) 90±190 417±184* 
Pre-switch memory (IgD+27+) 352±323 1111±378* 
Post-switch memory (IgD-27+) 655±511 1718±731* 
DN (IgD-27-) 357±455 876±248* 
 
* p < 0.05 in comparison with established RA patients before TNF inhibitors 
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Table 16. MFI values of CD86 on B cell subpopulations before and after TNF inhibitors.  Represented values are mean 
± SD. 
 Before TNF inhibitor After TNF-inhibitor 
CD19 157±68 69±137* 
NaÏve (IgD+27-) 70±117 Neg* 
Pre-switch memory (IgD+27+) 190±105 130±172 
Post-switch memory (IgD-27+) 256±122 269±151 
DN (IgD-27-) 161±78 164±102 
 
* p < 0.05 in comparison with established RA patients before TNF inhibitors 
 
5. Quantification of B cell cytokines and chemokines 
To analyze the cytokine and chemokine environment in circulation directly related with B cell 
activation, the serum levels of sCD23, a marker of B cell maturation [123-125] and CXCL13, 
an important B cell chemokine [126-128] were determined by ELISA in serum samples from 
all patients and healthy controls. 
 
5.1. ERA patients, but not established RA, have higher sCD23 levels in circulation 
It was observed that sCD23 levels were significantly higher in ERA patients when compared 
to healthy controls (p=0.0240) and established RA patients treated with MTX pre-bio 
(p=0.0147) (Figure 5). Furthermore, no significant differences were found in sCD23 levels in 
all established RA patients irrespective of treatment in comparison with controls. 
 
 
Figure 5. sCD23 serum levels are increased in ERA patients, but not in established RA irrespective of treatment; * p < 0.05 in 
comparison with Controls, ** p < 0.05 in comparison with ERA.  
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5.2. Serum CXCL13 levels are increased in ERA and established RA patients 
The B cell chemokine CXCL13 was significantly increased in ERA (p=0.0018) and 
established RA patients treated with MTX (p=0.0075), MTX pre-bio (p=0.0006) and TNF 
inhibitors (p=0.0326) when compared to healthy controls (Figure 6). However, no significant 
differences were observed in CXCL13 serum levels in established RA patients after TCZ 
treatment when compared to controls. 
 
 
 
Figure 6. CXCL13 serum levels are increased in ERA and established RA patients treated with MTX, MTX pre-bio and TNF 
inhibitors; * p < 0.05 in comparison with Controls. 
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V. DISCUSSION AND CONCLUSIONS 
Several studies have reported the importance of B cells in RA pathogenesis through diverse 
mechanisms [13, 129, 130]. B cells can produce autoantibodies (RF and anti-CCP), which 
can form immune complexes that deposit in the joints, causing inflammation; function as 
APCs and activate T cells; release cytokines once activated and participate in ectopic 
lymphoid neogenesis [13, 15, 23, 71, 76, 85]. In the present study, an extensive 
characterization of B cell phenotype was performed in untreated early RA patients with less 
than 1 year of disease duration and compared to established treated RA patients and healthy 
individuals. 
Abnormalities in the distribution of peripheral blood B cells have been previously reported in 
RA patients [120, 131], but there is still no consensus about this subject. In fact, while some 
studies have reported a decrease in memory B cells in circulation, other works have found an 
increase or no changes in the frequencies of circulating B cells, particularly memory B cell 
subsets, not only in RA but also in other autoimmune conditions [120, 131-135].  
The human memory B cell population is heterogeneous, comprising mutated pre-switch 
IgD+CD27+, post-switch IgD-CD27+ and double negative IgD-CD27- memory B cells [136, 
137]. It is widely accepted that post-switch IgD-CD27+ memory B cells are post-GC highly 
mutated memory B cells [137, 138]. Previous studies by our group have reported that very 
early RA patients (with less than 6 weeks of disease duration) have lower frequencies of 
circulating pre-switch IgD+CD27+ memory B cells [120] an unclass-switched memory B cell 
subset that plays a crucial role in early immune responses by producing high-affinity IgM. Of 
note, it has been demonstrated that memory B cells accumulate in the synovial membrane of 
RA patients, suggesting that the accumulation of pre-switch memory cells within inflamed 
tissue may contribute to a decrease in peripheral blood [120, 131]. Other studies have found 
that RA patients with long-standing disease have increased circulating levels of post-switch 
memory B cells and that this memory B cell subset also highly infiltrates synovial membranes 
in RA [131], which was suggested to be associated with a persistent immunological 
stimulation that would be enough to over-compensate the enhanced sequestration of these 
cells in the synovium.  
In the present study, although no differences were found in the frequencies of total CD19+ B 
cells in circulation, it was observed that established RA patients treated with MTX and MTX 
pre-bio had higher frequencies of circulating double negative (IgD-CD27-) B cells when 
compared to healthy controls. These changes can be related either with the effect of MTX 
treatment and/ or with disease activity, or disease duration [134, 139]  
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To better characterize the B cell phenotype in early and established RA patients, several 
cellular markers were studied which were directly related with B cell activation through BAFF 
(BAFF-R, TACI and BCMA); cellular activation (HLA-DR, CD69 and CD86); B cell 
chemotaxis (CXCR5); Fas-mediated apoptosis (CD95); BCR-mediated activation (IgM); B 
cell differentiation and maturation (CD5); and activation mediated by TLRs (TLR9). 
BAFF is a fundamental cell survivor factor essential for B cell proliferation and activation, and 
it has been suggested that this cytokine may be a potential target in B cell-related auto-
immune diseases. BAFF binds to 3 receptors: BAFF-R, TACI and BCMA, but the precise 
mechanisms that control the expression of all 3 BAFF receptors are currently unclear [140]. 
Previous studies by our group have demonstrated that BAFF levels are increased in RA 
patients in serum and locally in the joints in synovial fluid [141]. Furthermore, it has also been 
demonstrated that BAFF-R and TACI gene expression increase with disease progression 
[142, 143]. Nevertheless, these results were obtained at the gene level, not at the protein 
level. In the present work, no significant differences were detected in the expression levels of 
both BAFF-R and BCMA in all groups, but TACI expression was increased in total CD19+ B 
cells, particularly in post-switch memory B cells, in established RA after treatment with TNF 
inhibitors. The results observed for BAFF-R are in accordance with previous studies, where 
no differences were detected in comparison with healthy controls [108]. Studies with 
knockout mice have shown that B cell proliferation depends on either BAFF-R or TACI 
signaling. BAFF-R signaling can result not only in survival enhancement, but also in B cell 
maturation, while TACI triggering can stimulate class-switching and plasma cell 
differentiation [144, 145]. However, the functional activity of TACI is ambiguous [145, 146]. 
TACI provides positive signals driving T-independent B cell responses, but also delivers 
negative signals suppressing B cell activation [143, 147]. It is possible that the increased 
TACI expression observed after anti-TNF treatment results from a direct effect of the 
treatment. Increased TACI could deliver inhibitory signals to activated B cells, namely post-
switch memory B cells. Since BAFF binds with higher affinity to BAFF-R, leading to B cell 
activation [143] the increased levels of TACI could compete for BAFF-binding and thus 
induce an inhibitory effect on B cell activation as a consequence of anti-TNF treatment. 
Moreover, the normal expression levels observed for BCMA in all groups analyzed can be 
related to the fact that this receptor is mainly expressed at later stages of B cell 
differentiation, namely by plasma cells [148, 149].  
Previous studies have reported that B cells once activated increase the expression of 
activation markers such as HLA-DR, CD69 and CD86 [100, 150], which are expressed in 
small amounts or not at all on resting B cells. In the present work, although no differences 
were detected in CD69 and CD86 expression levels in all B cell subpopulations in all groups 
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analyzed, HLA-DR expression was increased in established RA patients after treatment with 
TNF inhibitors and TCZ. It has been demonstrated that treatment options administrated to 
RA patients are able not only to ameliorate clinical symptoms, but also to diminish the 
cellular infiltration in the joints [55, 60, 151]. It is possible that due to the effect of anti-TNF 
and TCZ treatments, activated B cells infiltrating the synovial membrane of established RA 
patients return to the peripheral blood and re-circulate. These activated B cells express 
higher levels of HLA-DR, in accordance with their function as APCs locally in the joints [12, 
30, 152]. Nonetheless, the absence of differences in CD69, an early activation marker [153], 
and CD86, a costimulatory molecule important for B-T cell interactions [154] [155], in all 
studied groups might indicate that the activation state of peripheral blood B cells is lower 
than in B cells recruited to the joints, where the main inflammatory process occurs in RA. 
Furthermore, the decreased CD86 expression observed in established RA patients treated 
with TNF inhibitors when compared to baseline levels further supports an effect of anti-TNF 
therapies in inhibiting B cell activation state, which is in accordance with previous studies 
[156]  
Apoptosis through engagement of the death receptor Fas (CD95) plays pivotal roles in 
maintaining peripheral immune self-tolerance [157]. Importantly, defects in apoptosis, namely 
in the CD95-dependent death receptor pathway, have been demonstrated to occur in RA 
pathogenesis [158, 159]. The increased CD95 MFI values observed in post-switch memory B 
cells in established RA patients after treatment with TNF inhibitors and TCZ when compared 
to controls are probably a direct consequence of treatment as a mean to counteract B cell 
activation and autoimmunity. Thus, a higher level of expression of CD95 after treatment with 
anti-TNF and/ or TCZ, turns B cells more prone to apoptosis, which is in accordance with 
recent reports [160]. Since this observation was specifically detected in post-switch memory 
B cells, this supports the relevance of this B cell subpopulation in RA pathogenesis as 
previously demonstrated [131]. Furthermore, the increase in CD95 expression levels in all B 
cell subpopulations in established RA patients after treatment with TNF inhibitors when 
compared to baseline levels are in accordance with recent reports that suggest that TNF 
inhibitors have the ability to modulate Fas-mediated apoptosis in RA [160]. 
In this work, decreased frequencies of CD5+ B cells were observed in all groups of RA 
patients studied in comparison with healthy controls. Previous studies have found alterations 
in these cells not only in RA, but also in other autoimmune diseases [161-163]. CD5+ B cells 
are known to be associated with bone resorption through IL-6 production, a cytokine that 
supports osteoclast differentiation [161, 164, 165]. The decreased frequency of these cells in 
circulation in all patients’ groups could result from a recruitment of CD5+ B cells towards the 
synovial membrane, where the main inflammatory process occurs in RA, which would 
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contribute for bone erosion. Furthermore, increased CD5 MFI values were also detected on 
B cells in established RA patients after treatment with TNF inhibitors and TCZ. CD5 has also 
been suggested as a negative regulator of B cell activation [166]. Thus, it is possible that the 
increased expression of CD5 on B cells after anti-TNF and TCZ treatments constitutes a way 
to counteract the development of autoimmunity. In fact, CD5+ B cells have also been 
suggested to be precursors of regulatory B cells [167, 168] which further supports the results 
observed. 
B cell stimulation through TLRs can also be a mechanism directly related with autoimmunity 
[169]. TLR9 recognizes unmethylated microbial CpG DNA, which in turn is similar to certain 
CpG DNA motifs within the mammalian genome [170, 171]. Supporting the involvement of 
TLR9 signaling in the development of autoimmunity, hypomethylated genomic CpG DNA has 
been found in RA and SLE patients [171]. Moreover, it is known that the dual engagement of 
BCR and TLR9 may activate autoreactive B cells that recognize endogenous CpG DNA 
released from apoptotic cells and CpG DNA-IgG immune complexes in RA joints, and induce 
their development into RF-producing B cells [171, 172]. Also, stimulation through TLRs, 
namely TLR9, can be more efficient than T-dependent pathways at downregulating BAFF-R 
expression on memory B-cell populations [173]. Of note, it has been demonstrated that TLR7 
and TLR9 triggering strongly upregulate TACI expression [121, 173], which suggests that 
autoimmunity might also be correlated with reciprocal induction and activation of TACI and 
TLRs [143, 172, 173]. In this study, increased TLR9 expression was observed in all B cell 
subpopulations in established RA patients after treatment with TCZ when compared to 
controls. Also, increased TLR9 MFI values were detected on post-switch memory and DN B 
cells in MTX treated patients in comparison with controls. These observations might indicate 
that although MTX and TCZ treated RA patients have the lowest disease activity scores, B 
cells may have escape mechanisms through TLR9-mediated activation to perpetuate 
autoimmunity. 
CXCR5 is a chemokine receptor highly expressed in recirculating B cells, in subsets of CD4+ 
and CD8+ T cells and monocytes [117, 174-176]. CXCR5 and its ligand, CXCL13, involved in 
B cell chemotaxis, are upregulated in RA synovium, suggesting a local role in B cell 
recruitment toward the synovial membrane [117, 174, 175, 177]. In this study, increased 
CXCR5 expression levels were observed on B cells from untreated ERA and established RA 
patients after treatment with MTX and TNF inhibitors, which supports B cell recruitment 
towards the joints since early RA onset. Moreover, the increased serum CXCL13 levels 
found in all patients groups when compared to controls further corroborate an upregulation of 
B cell chemotaxis in RA [12, 175, 176]. 
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CD23, the low-affinity Fc receptor for IgE, is a C-type lectin that has a membrane (mCD23) 
and a soluble form (sCD23) and each form binds to multiple ligands and exerts diverse 
physiologic functions. During the activation of normal B cells, mCD23 is cleaved by a cell-
associated protease and released as sCD23 [123, 124, 178]. Several authors have 
described increased levels of sCD23 in RA patients and their association with joint erosion 
[123, 179]. It has been suggested that the increased serum levels of sCD23 in RA patients 
are due to a higher expression of mCD23 on CD5+ B cells [162]. In this study, the increased 
serum sCD23 levels detected in untreated ERA patients in comparison with controls can be 
related with an early B cell and macrophage activation [180]. 
To sum up, established RA patients have disturbances in the frequencies of memory B cell 
subpopulations in circulation, namely in double negative IgD-CD27- B cells. Also, the 
expression levels of cellular markers can be affected by TNF inhibitors and TCZ treatment, 
particularly activation markers (HLA-DR, CD86). Furthermore, untreated ERA patients have 
significantly decreased frequencies of CD5+ B cells, elevated CXCR5 expression and higher 
serum CXCL13 levels in comparison with controls, which supports an early B cell activation 
in RA pathogenesis as previously suggested [120, 141].  
 
VI. FUTURE PERSPECTIVES 
In order to expand and further complete this study it would also be important to do some in 
vitro assays with B cell stimuli (anti-IgM, BAFF, CpG motifs…) using isolated B cell subsets 
to better characterize B cell subpopulations and their activation pattern. Simultaneously, 
apoptosis studies could also be performed. Moreover, increasing the cohorts of patients and 
extending the time between baseline and follow-up blood collection dates would also allow a 
more robust statistical analysis. It would also be important to study the effects of treatment 
options individually in particular all TNF inhibitors available (infliximab, adalimumab, 
certolizumab, golimumab and etarnecept), since it is possible that different drugs can have 
different effects. Of note, it would also be interesting to study other therapeutic approaches 
such as the B cell depleting drug rituximab and/ or abatacept, a fusion protein composed of 
the Fc region of the immunoglobulin IgG1 fused to the extracellular domain of CTLA-4 that 
inhibits T cell activation. Furthermore, in order to have a more complete discrimination 
between B cell subpopulations, the use of IgD/ CD38 system classification could be very 
useful, since it allows the identification of six B cell subpopulations, contrarily to IgD/CD27. 
Indeed, the conjugation of the results obtained with the two classification systems would 
allow a more complete analysis of B cell subsets.  
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APPENDIX 1 
 
1. 2010 ACR/EULAR classification criteria for rheumatoid arthritis [8] 
 
* The criteria are aimed at classification of newly presenting patients. In addition, 
patients with erosive disease typical of rheumatoid arthritis (RA) with a history compatible 
with prior fulfillment of the 2010 criteria should be classified as having RA. Patients with 
longstanding disease, including those whose disease is inactive (with or without treatment) 
who, based on retrospectively available data, have previously fulfilled the 2010 criteria 
should be classified as having RA.  
† Differential diagnoses vary among patients with different presentations, but may 
include conditions such as systemic lupus erythematosus, psoriatic arthritis, and gout. If it is 
unclear about the relevant differential diagnoses to consider, an expert rheumatologist 
should be consulted.  
‡ Although patients with a score of <6/10 are not classifiable as having RA, their 
status can be reassessed and the criteria might be fulfilled cumulatively over time.  
§ Joint involvement refers to any swollen or tender joint on examination, which may 
be confirmed by imaging evidence of synovitis. Distal interphalangeal joints, first 
carpometacarpal joints, and first metatarsophalangeal joints are excluded from assessment. 
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Categories of joint distribution are classified according to the location and number of involved 
joints, with placement into the highest category possible based on the pattern of joint 
involvement.  
¶ “Large joints” refers to shoulders, elbows, hips, knees, and ankles. 
 # “Small joints” refers to the metacarpophalangeal joints, proximal interphalangeal joints, 
second through fifth metatarsophalangeal joints, thumb interphalangeal joints, and wrists. ** 
In this category, at least 1 of the involved joints must be a small joint; the other joints can 
include 40 any combination of large and additional small joints, as well as other joints not 
specifically listed elsewhere (e.g., temporomandibular, acromioclavicular, sternoclavicular, 
etc.).  
††Negative refers to IU values that are less than or equal to the upper limit of normal (ULN) 
for the laboratory and assay; low-positive refers to IU values that are higher than the ULN but 
≤3 times the ULN for the laboratory and assay; high-positive refers to IU values that are >3 
times the ULN for the laboratory and assay. Where rheumatoid factor (RF) information is only 
available as positive or negative, a positive result should be scored as low-positive for RF.  
‡‡ Normal/abnormal is determined by local laboratory standards. 
 §§ Duration of symptoms refers to patient self-report of the duration of signs or symptoms of 
synovitis (e.g., pain, welling, tenderness) of joints that are clinically involved at the time of 
assessment, regardless of treatment status. 
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APPENDIX 2 
 Classification of CD19+ B cell subpopulations 
 
Circulating B cell (CD19+) subpopulations were defined according to IgD and CD27 
expression and classified as naïve(IgD+CD27-), pre-switch-memory (IgD+CD27+), post-
switch memory (IgD-CD27+) and double-negative (IgD-CD27-) B cells. 
 
 
Circulating B cell (CD19+) subpopulations were defined according to IgD and CD38 
expression and classified as IgD+ memory (IgD+CD38-), naïve (IgD+38+), transitional 
(IgD+CD38++), resting memory (IgD-CD38-), post-GC memory (IgD-CD38+) B cells and 
plasmablasts (IgD-CD38++). In this study this classification was only used to analyze 
plasmablasts (IgD-CD38++). 
 
